Article Sidebar

pdf
Date Published: 05/01/2026
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v557i3.16808
Issue
Vol. 557 No. 3 (2025)
Section
Các bài báo
How to Cite
Hoàng, T. H., Đỗ, T. Q., & Lê, Q. T. (2026). HYPOTHYROIDISM INCIDENCE IN GRAVES’ DISEASE PATIENTS AFTER I-131 TREATMENT FOR 12 MONTHS AT CENTRAL ENDOCRINOLOGY HOSPTAL. Vietnam Medical Journal, 557(3). https://doi.org/10.51298/vmj.v557i3.16808

HYPOTHYROIDISM INCIDENCE IN GRAVES’ DISEASE PATIENTS AFTER I-131 TREATMENT FOR 12 MONTHS AT CENTRAL ENDOCRINOLOGY HOSPTAL

Thị Hiền Hoàng, Trung Quân Đỗ, Quang Toàn Lê

Main Article Content

Abstract

Objectives: To determine the incidence of hypothyroidism in Graves' disease patients after treatment with I-131 for 12 months at the Central Endocrinology Hospital, and to identify associated factors related to hypothyroidism in the studied group. Method: A descriptive observational study was conducted on 116 Graves' disease patients indicated for I-131 treatment who treated at the Central Endocrinology Hospital. Results: The incidence of hypothyroidism after treatment with I-131 for 12 months was 64.7%. Patients turned to hypothyroidism from the 2nd to the 6th month after I-131 treatment. The percentage of hypothyroidism within the first 6 months after treatment was 90.1%. The hypothyroid group had a smaller pre-treatment thyroid volume (25,7 ± 13 and 32,6 ± 12,9, p<0,05), lower pre-treatment T3 concentration (3,8 ± 1,7 and 4,6 ± 2,5, p < 0,05) and lower I-131 dose (6,7 ± 1,9 and 7,6 ± 1,5, p<0,05) compared to the non-hypothyroid group. Conclusion: The rate of hypothyroidism one year after I-131 treatment in patients with Graves' disease is 64.7%. The most common time for the occurrence of hypothyroidism is within the first 6 months after treatment. Patients with smaller thyroid gland size and lower pre-treatment T3 levels have an increased risk of hypothyroidism following I-131 treatment

Article Details

Keywords

Hypothyroidism, Graves' disease, I-131

References

LIỆU THAM KHẢO
1. Bộ Y tế (2014). Quyết định 5204 về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị bệnh bằng Y học hạt nhân”.
2. Ngô Quang Bảy (2016). Bệnh cường giáp. Bệnh học Nội khoa Tập 2. Nhà xuất bản Y học, Hà Nội.
3. Nguyễn Thị Giang An và Nguyễn Quang Trung (2021). Ảnh hưởng của I ốt phóng xạ (131I) lên các tế bào máu của bệnh nhân ung thư tuyến giáp thể biệt hóa. Tạp chí Công nghệ Sinh học, 19(3):449-457.
4. Trần Thừa Nguyên và Đào Thị Dừa (2021). Nghiên cứu hiệu quả điều trị Idoe phóng xạ (I131) ở bệnh nhân basedow tại Bệnh viện Trung ương Huế. Tạp chí “Nội tiết và Đái tháo đường”, 44:82-88
5. Beslic N, Licina S, Sadija A, Milardovic R (2017). Incidence of Hypothyreoidism after Radioactive Iodine-I131 Treatment in Dependance of Hyperthyreoidism Etiology and Therapy Dose. Med Arch, 71(4):270-273.
6. Franklyn JA, Daykin J, Drolc Z et al (1994). Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf), 34(1):71-6. doi:10.1111/j.1365-2265.1991.tb01738.x.
7. Lewis A, Atkinson B, Bell P, et al (2013). Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J, 82(2):85-8.
8. Schüssler-Fiorenza CM, Bruns CM, Chen H (2006). The surgical management of Graves' disease. J Surg Res, 133(2):207-14.
9. Zhao A., Zhan J., Xue J et al (2024). Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves’ disease in different periods. Sci Rep, 14, 31148.